Articles tagged with: Pomalidomide
Now that Pomalyst has been approved in the United States as a treatment for multiple myeloma, the drug is available for physicians in the U.S. to prescribe for their patients.
The broad availability of Pomalyst, however, raises the important question: For what types of myeloma patients are physicians likely to prescribe Pomalyst?
Early this month, the U.S. Food and Drug Administration (FDA) approved Pomalyst (pomalidomide) for the treatment of certain multiple myeloma patients. These patients must have received at least two prior therapies, including Revlimid (lenalidomide) and
On Friday, the U.S. Food and Drug Administration (FDA) approved Pomalyst (pomalidomide) for the treatment of multiple myeloma patients who have received at least two prior therapies (see related Beacon news).
In this article, The Beacon addresses important questions multiple myeloma patients have been asking about the FDA decision. The article is organized similarly to one the Beacon published about Kyprolis (carfilzomib) after it was approved by the FDA last summer.
What exactly did …
Specifically, Pomalyst has been approved for use in patients with multiple myeloma who have received at least two prior therapies including Revlimid (lenalidomide) and Velcade (bortezomib) and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Celgene (NASDAQ:CELG), the company that will market Pomalyst, has told The Beacon that the drug …
The “what will the FDA decide about pomalidomide” waiting game is reaching its final hours, and the drama is peaking.
Celgene (CELG:NASDAQ), the company that has been developing pomalidomide, asked the U.S. Food and Drug Administration (FDA) last April to approve the drug for the treatment of relapsed and refractory myeloma.
Based on the date the company filed its new drug application with the FDA, the regulator is required to make a decision on the application by this coming Sunday, February 10.
Financial analysts are expecting a positive …
Celgene has proposed ‘Pomalyst’ as the trademarked brand name for pomalidomide.
The name was made public this morning in a press release by Celgene (NASDAQ: CELG), the company developing pomalidomide. The press release contains information about the company’s expected financial results for 2012 and forecasts for 2013 and later years.
In the press release, Celgene refers to pomalidomide primarily by its new proposed brand name, Pomalyst. This is the first time the company has used the proposed brand name in a public document or presentation.
Pomalidomide belongs to …